- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CEACAM1 antibody, also known as Biliary glycoprotein 1 antibody, recognizes Carcinoembryonic antigen-related cell adhesion molecule 1, a type I transmembrane glycoprotein encoded by the CEACAM1 gene and commonly referred to as CD66a and BGP-1. CEACAM1 is a member of the carcinoembryonic antigen-related cell adhesion molecule family within the immunoglobulin superfamily and is primarily localized to the plasma membrane of epithelial and immune cells. It is expressed in liver, biliary epithelium, intestine, prostate, and mammary gland, as well as in subsets of activated T cells, B cells, and natural killer cells, supporting epithelial organization and immune regulation.
CEACAM1 antibody detects a protein composed of extracellular immunoglobulin-like domains, a single transmembrane region, and alternatively spliced cytoplasmic tails. Long cytoplasmic isoforms contain immunoreceptor tyrosine-based inhibitory motifs that recruit phosphatases and regulate downstream signaling pathways controlling proliferation, differentiation, and apoptosis. Short isoforms lack these motifs and display altered regulatory capacity. In polarized epithelial tissues, Biliary glycoprotein 1 is enriched at apical and lateral membranes, contributing to maintenance of glandular architecture and barrier integrity while integrating adhesion-dependent signaling events.
Beyond its structural role, CEACAM1 functions as a signaling receptor in immune cells. Frequently referred to as CD66a in immunophenotyping contexts, CEACAM1 can act as a co-inhibitory receptor that modulates T cell activation, tolerance, and inflammatory responses. Through these mechanisms, CEACAM1 participates in immune homeostasis and tumor-immune interactions. Several bacterial and viral pathogens utilize CEACAM family members as host receptors, underscoring the importance of Biliary glycoprotein 1 in host-pathogen interaction studies and mucosal immunity research.
Altered CEACAM1 expression has been reported in colorectal carcinoma, hepatocellular carcinoma, breast cancer, melanoma, and prostate cancer. In certain epithelial malignancies, reduced expression correlates with decreased cell adhesion and increased invasiveness, while in other tumor types elevated CEACAM1 levels are associated with tumor progression and immune modulation. These context-dependent findings highlight the relevance of CEACAM1 antibody for evaluating membrane protein expression in normal tissue biology and disease-associated models.
The CEACAM1 antibody (clone CEACAM1/4840) is suitable for detecting Biliary glycoprotein 1 expression in research applications. This Biliary glycoprotein 1 antibody supports investigation of adhesion molecule dynamics, isoform-specific signaling differences, and tumor-associated changes in CEACAM1 expression.
Optimal dilution of the CEACAM1 antibody should be determined by the researcher.
A recombinant partial protein sequence (within amino acids 50-250) from the human protein was used as the immunogen for the CEACAM1 antibody.
Aliquot the CEACAM1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.